[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100295411":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":40,"centralContacts":44,"locations":49,"responsibleParty":67,"collaborators":24,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":24,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":24,"studyType":83,"phases":84,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":52,"whyStopped":24,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"4SCAR19 and 4SCAR20\u002FCD22\u002FCD30\u002FCD38\u002FCD70\u002FCD123","EXPERIMENTAL","Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20\u002FCD22\u002FCD30\u002FCD38\u002FCD70\u002FCD123-specific gene-engineered T cells.",[13,14,15,16,17,18],"Biological: 4SCAR19 and 4SCAR22","Biological: 4SCAR19 and 4SCAR38","Biological: 4SCAR19 and 4SCAR20","Biological: 4SCAR19 and 4SCAR123","Biological: 4SCAR19 and 4SCAR70","Biological: 4SCAR19 and 4SCAR30",[20,25,28,31,34,37],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","4SCAR19 and 4SCAR22",[9],null,{"type":21,"name":26,"description":26,"armGroupLabels":27,"otherNames":24},"4SCAR19 and 4SCAR38",[9],{"type":21,"name":29,"description":29,"armGroupLabels":30,"otherNames":24},"4SCAR19 and 4SCAR20",[9],{"type":21,"name":32,"description":32,"armGroupLabels":33,"otherNames":24},"4SCAR19 and 4SCAR123",[9],{"type":21,"name":35,"description":35,"armGroupLabels":36,"otherNames":24},"4SCAR19 and 4SCAR70",[9],{"type":21,"name":38,"description":38,"armGroupLabels":39,"otherNames":24},"4SCAR19 and 4SCAR30",[9],[41],{"name":42,"affiliation":5,"role":43},"Lung-Ji Chang, PhD","PRINCIPAL_INVESTIGATOR",[45],{"name":42,"role":46,"phone":47,"phoneExt":24,"email":48},"CONTACT","+86 0755-86573763","c@szgimi.org",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":59,"coordinates":60},"Point",[61,62],114.0683,22.54554,{"lat":62,"lon":61},[65],{"name":42,"role":46,"phone":66,"phoneExt":24,"email":48},"86-13671121909",{"type":43,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Lung-Ji Chang","President","100295411","phase-1-combination-car-t-cell-therapy-targeting-hematological-malignancies-100295411",false,"NCT03125577","Combination CAR-T Cell Therapy Targeting Hematological Malignancies","Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies","Inclusion Criteria:\n\n1. age older than 6 months.\n2. malignant B cell surface expression of CD19\u002FCD20\u002FCD22\u002FCD30\u002FCD38\u002FCD70\u002FCD123 molecules.\n3. the KPS score over 80 points, and survival time is more than 1 month.\n4. greater than Hgb 80 g\u002FL.\n5. no contraindications to blood cell collection.\n\nExclusion Criteria:\n\n1. accompanied with other active diseases, the treatment is difficult to assess patient response.\n2. bacteria, fungus, or virus infection, unable to control.\n3. living with HIV.\n4. active HBV and HCV infection.\n5. pregnant and nursing mothers.\n6. under systemic steroid treatment within a week of the treatment.\n7. prior failed CAR-T treatment.","ALL","6 Months","75 Years",{"count":81,"type":82},100,"ESTIMATED","INTERVENTIONAL",[85,86],"PHASE1","PHASE2","The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I\u002FII trial enrolling patients from multiple clinical centers.",[89],"B-cell Malignancies",[91,92,93,94,95,96,97,98,99,100],"4S CAR-T","CD19","CD20","CD22","CD38","CD123","B cell leukemia","B-ALL","CD70","CD30","2026-06-18",{"date":103,"type":104},"2026-06-23","ACTUAL",{"date":106,"type":104},"2025-08-01",{"date":108,"type":82},"2029-12-31",{"name":5,"class":6},1]